Dahnuka Agritech –
Q2 FY 25 results and concall highlights –
Revenues – 654 vs 618 cr, up 6 pc
Gross Margins @ 42 vs 40 pc
EBITDA – 160 vs 142 cr, up 12 pc ( margins @ 24.3 vs 22.9 pc )
PAT – 118 vs 102 cr, up 16 pc
Guidance for FY 25 – revenue growth of aprox 15-16 pc over FY 24. EBITDA margin improvement of 100 bps ( 1 pc ) over FY 24. Earlier they had guided for a 20 pc topline growth for FY 25 – basically have made a downward revision to their projections
Continuous / Excess rainfall in Aug/Sep resulted in farmers skipping sprays in many crops ( specially insecticides ). Sales return from Q1 also had an adverse effect on the topline growth
There was a continued pricing pressure on product prices ( to the tune of 4-5 pc ) resulting in lower topline growth
Three of company’s newly launched products – Purge ( Japanese herbicide for Groundnut and Soybean ), Lanevo ( insecticide for horticulture crops ) and Myco Super ( biologic – for soil health ) – are doing exceedingly well in the marketplace and exceeding even the company’s expectations. Both Purge and Lanevo are in-licensed from Nissan ( Japan )
Product wise sales breakup in Q2 –
Insecticides – 43 pc
Fungicides – 21 pc
Herbicides – 17 pc
Others – 19 pc
Region wise sales breakup in Q2 –
North – 29 pc
South – 31 pc
East – 12 pc
West – 28 pc
The patented products ( that the company in-licesnces ) from Innovators – contribute to aprox 600 cr of company’s topline at present. Have tie-ups with 10 leading agrochemical companies across the world in order to tap into in-licensing opportunities
Company is currently serving aprox 1 cr farmers through a network of 41 warehouses, 6500 distributors, 80k + retailers
High water levels in reservoirs should support a strong Rabi season this FY – augurs well for the company
Company did not share their launch pipeline for next FY
Company new AI plant at Dahej generated revenues of Rs 8 cr in Q2. Did operate at negative EBITDA levels { aprox (-) 4 cr }
Sales return in Q2 were due to late onset of monsoons and excessive rains. Sales returns were aprox – 100 cr, mostly in the herbicides category ( general levels of sales returns in Q2 are around 50-60 cr )
Volume growth for Q2 was 10 pc. Price growth was (-) 4 pc
Not expecting any significant sales returns in Q3
High inventory build up at the end of Q2 is also due to increased sales returns. Company expects the same to normalise by end of FY 25
Company has been able to hold onto and improve their gross margins is because of good / great performance from their in-licensed speciality portfolio. Price erosion in generic products has been much higher
Zanet ( another in-licensed product launched LY – fungicide used on Potato, Tomato crops ) is also doing very well
All 4 products – Zanet, Lanevo, Myco Super and Purge are exclusively with Dhanuka. The same is likely to continue for medium term
At present – company derives 33 pc of its revenues from In-Licensed products
Company makes 10-15 pc extra gross margins on these exclusive – inlicensed products. Generally, company starts with 3-5 yrs exclusivity agreements with the innovators. The same is extendable after that
Looking for Contract manufacturing opportunities from the Dahej plant. Nothing has fructified as of now. Aim to do a 250 cr revenues from the Dahej plant by end of FY 27
Other big brands from company’s stable include – Targa Super ( herbicide ), Caldan ( insecticide ), Sempra ( herbicide ), Mortar ( insecticide ) and Decide ( insecticide ). However, the company did not specify these product’s annual sales except that Targa is the only > 100 cr brand among these. Others have the potential to reach that milestone in medium term
Should start to break even from Dahej once revenues from the facility cross 150 cr
Disc: holding, biased, not SEBI registered, not a buy/sell recommendation
| Subscribe To Our Free Newsletter |
